Abstract:Coherence in the phase of oscillatory neuronal activity indicates functional interaction among brain regions at rest. Infra-slow fluctuations in BOLD signal (band 5 - 0.01 to 0.027 Hz - and band 4 - 0.027 to 0.073 Hz) has been observed using resting state fMRI when employing frequency-domain analysis, and has been previously shown to be altered in schizophrenia. In the current study, we examined the strength and the dynamic variance of phase coherence in these 2 bands (using a sliding window approach) among 6 large-scale brain networks (default-mode, fronto-parietal, salience, sensorimotor, visual, cerebellar) in 129 drug-naïve patients with schizophrenia and 197 healthy controls. Our motivation was to exploit the large-scale resting-state slow-wave oscillatory dynamics to parse the heterogeneity of schizophrenia. Four 6*6 matrices depicting patient vs. control differences in dynamic variance and mean of phase coherence (vPC and mPC respectively) in the slow 4 and slow 5 bands were constructed from resting state fMRI time series obtained from 6 networks based on 160 nodes of Dosenbach’s atlas. Deviations in mean/variance of phase coherence among the 6 networks were identified after FDR correction for each matrix (p<0.05). A latent profile analysis (LPA) was undertaken on the basis of the identified deviant features in the patient group. LPA is a Finite Mixture Modelling approach to identify naturally occurring sub-groups of patients on the basis of multivariable data. The identified subgroups were compared in terms of the severity of clinical symptoms across van der Gaag’s 5 factors of PANSS scale. Patients with schizophrenia showed increased vPC between salience-sensorimotor and visual-cerebellar networks in band 5; decreased vPC between DMN-sensorimotor and DMN-cerebellar networks in band 4. Patients also had a decrease in mPC between DMN-visual and DMN-cerebellar networks in band 5. We were able to identify 3 subgroups of patients using LPA. SZ1 (n=28) and SZ2 (n=45) had higher overall burden of symptoms compared to SZ3 (n=56). SZ2 had the highest burden of negative syndrome score and showed most deviance from healthy controls (5 out of 7 features significantly different from the healthy cohort). SZ1 had the highest burden of positive syndrome scores and had 4 out of 7 features deviant from HC. In contrast, SZ3 had least deviation from HC (3 out of 7 features) and also had less symptom burden across all symptom dimensions. Various abnormalities have been reported in the interactions among the large-scale networks in schizophrenia, with lack of consistency ascribed to syndromic heterogeneity. We illustrate how deviations in time-varying nature of slow-wave oscillations in resting state fMRI can be exploited to meaningfully reduce heterogeneity of this illness. The 3 subgroups thus identified not only show differential symptom burden but also exhibit hierarchical deviation from a normative group of healthy controls (SZ2>SZ1>SZ3>HC). To our knowledge this is the first attempt to stratify ‘neurotypes’ among drug-naïve patients with schizophrenia on the basis of large-scale network dynamics. Given the widespread availability of resting-fMRI data, we anticipate independent replication of our results in the near future.

Exploring the Latent Cognitive Structure in Schizophrenia: Implications for Antipsychotic Treatment Responses.

O3.1. NEUROTYPING UNTREATED FIRST EPISODE SCHIZOPHRENIA ON THE BASIS OF SLOW-WAVE RESTING-STATE DYNAMICS

Identifying and Revealing Different Brain Neural Activities of Cognitive Subtypes in Early Course Schizophrenia

Intelligence As Proxy Phenotype Providing Insight into the Heterogeneity of Schizophrenia

Factor structures of the neurocognitive assessments and familial analysis in first-episode schizophrenia patients, their relatives and controls.

Distinct Neuroanatomic Subtypes in Antipsychotic-Treated Patients with Schizophrenia Classified by the Predefined Classification in a Never-Treated Sample

Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Overlap between individual differences in cognition and symptoms of schizophrenia

Brain-clinical Pattern Alterations after Treatment in Schizophrenia.

Cognitive subgroups of affective and non-affective psychosis show differences in medication and cortico-subcortical brain networks

Resilience and Cognitive Function in Patients With Schizophrenia and Bipolar Disorder, and Healthy Controls

Cognitive Deficits, Clinical Variables, and White Matter Microstructure in Schizophrenia: a Multisite Harmonization Study

M61. Data-Driven Approach Identified Functionally and Physiologically Distinct Psychosis Subtypes

Symptom Dimensions and Cognitive Impairments in Individuals at Clinical High Risk for Psychosis

Individual Differences in Schizophrenia.

Hippocampus and Cognitive Domain Deficits in Treatment-Resistant Schizophrenia: A Comparison with Matched Treatment-Responsive Patients and Healthy Controls✰,✰✰,★,★★

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study

Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics

Deconstructing Cognitive Impairment in Psychosis With a Machine Learning Approach

Two Subtypes of Schizophrenia Identified by an Individual-Level Atypical Pattern of Tensor-Based Morphometric Measurement.